Press Releases

Via Oncology Pathways Expanding into New Market Segments through Strategic Collaboration with saleSEER, Inc.


PITTSBURGH, Oct. 11, 2012 /PRNewswire/ -- Via Oncology, a division of D3 Oncology Solutions, an affiliate of UPMC, announced today that it has engaged saleSEER, Inc. to begin offering access to Via Oncology Pathways content to a new market segment.  

Under the arrangement, saleSEER will provide all sales and marketing services for the licensing of the Via Oncology Pathways Portal to pharmaceutical, clinical research ("CRO") and other entities that do not provide direct care to patients.  To avoid conflicts of interest, the Via Oncology Pathways staff and disease committee members will not know the identities of the saleSEER customers.  The Pathways Portal provides these customers with insight into the process and resulting pathways of eighteen separate disease specific committees.  The subscriptions will provide access to real time pathways algorithms and supporting documentation and evidence reviews through a Pathways Portal with identical content to that used by Via Oncology customers.  

"The unique nature of the collaboration with saleSEER acting as a blinded broker allows for continued assurance against conflicts of interest by creating anonymity for the Via Oncology staff and physician disease committees as to the ultimate purchasers of the Via Oncology Pathways content," said Kathy Lokay, President and CEO of D3.   "Our partnership with saleSEER will expand our ability to share valuable insight into how academic and community based oncologists assess published data as it relates to the efficacy, toxicity and costs of various options as well as the unique patient scenarios requiring alternative approaches."

According to Peter Ellis, Medical Director for the Via Oncology Pathways and medical oncologist at UPMC CancerCenter, "Pharma is a key stakeholder in healthcare reform.  We hope to accelerate improvements in the value of cancer care by providing them with insight into the utilization of clinical trial data by oncologists when making patient care decisions."

Via Oncology Pathways cover more than 90% of cancer types and are updated quarterly by teams of academic and community based physicians using a disciplined process for data evaluation, providing unique insights for the oncology drug development market.

"This offering is very exciting because for the first time, industry is being provided with much needed insight into the data evaluation process and attribution of associated value with that data for studies," says Jean van Soelen, CEO of saleSEER. "It's a win-win because Via Oncology's evidence review process reveals and documents gaps in the data that all partners who value the most effective patient care can utilize to improve trial design."

Via Oncology ( is transforming cancer care at a time when increasing demands on cancer centers have placed quality and cost effectiveness at the forefront of health reform by enabling oncologists to stay on top of these changes in accountable care, proving their value to patients, payers and referring physicians.

 saleSEER, Inc. is a privately owned corporation with headquarters in Houston, TX.  The company specializes in providing clinical data and content commercialization services to the healthcare industry.


Joseph Vickless, Via Oncology

Jean vanSoelen, saleSEER


SOURCE Via Oncology Pathways